RT Journal Article
T1 Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.
A1 Isla, D
A1 de Castro, J
A1 García-Campelo, R
A1 Lianes, P
A1 Felip, E
A1 Garrido, P
A1 Paz-Ares, L
A1 Trigo, J M
K1 Accumulated toxicity
K1 Chemotherapy
K1 Delphi consensus
K1 Disease aggressiveness
K1 Immunotherapy
K1 Lung adenocarcinoma
K1 Nintedanib
K1 PD-L1 expression
K1 Prior treatment
K1 Progression-free interval
K1 Treatment decisions
K1 Tumour mutational burden
AB Immunotherapy-based approaches are standard first-line treatments for advanced/metastatic lung cancer or for chemoradiotherapy consolidation in locally advanced disease. Uncertainty on how to treat patients at disease progression prompted us to develop a consensus document on post-immunotherapy options in Spain for patients with advanced wild-type lung adenocarcinoma. After extensive literature review, a 5-member scientific committee generated 33 statements in 4 domains: general aspects (n = 4); post-durvalumab in locally advanced disease (n = 6); post-first-line immunotherapy ± chemotherapy in advanced/metastatic disease (n = 11); and post-first-line platinum-based chemotherapy in advanced/metastatic disease (n = 12). A panel of 26 lung cancer experts completed 2 Delphi iterations through an online platform rating their degree of agreement/disagreement (first-round scale 1-5 and second-round scale 1-4, 1 = strongly disagree, 4/5 = strongly agree) for each statement. Second-round consensus: ≥ 70% of responses were in categories 1/2 (disagreement) or 3/4 (agreement). Consensus was reached for 2/33 statements in the first Delphi round and in 29/31 statements in the second round. Important variables informing treatment at disease progression with an immunotherapy-based treatment include: disease aggressiveness, previous treatment, accumulated toxicity, progression-free interval, PD-L1 expression, and tumour mutational burden. A platinum-based chemotherapy should follow a first-line immunotherapy treatment without chemotherapy. Treatment with docetaxel + nintedanib may be appropriate post-durvalumab in refractory patients or following progression to first-line chemotherapy + immunotherapy, or second-line chemotherapy after first-line immunotherapy, or first-line chemotherapy in some patients with low/negative PD-L1 expression, or second-line immunotherapy after first-line chemotherapy. To support decision making following progression to immunotherapy-based treatment in patients with advanced wild-type lung adenocarcinoma, a consensus document has been developed.
YR 2019
FD 2019-07-31
LK http://hdl.handle.net/10668/14349
UL http://hdl.handle.net/10668/14349
LA en
DS RISalud
RD Apr 12, 2025